
AGO4: a potential new universal target for antiviral therapeutics
A team of researchers have uncovered a protein, AGO4, which may have the potential to be used as a therapeutic target to universally increase protection against viral pathogens.
A team of researchers have uncovered a protein, AGO4, which may have the potential to be used as a therapeutic target to universally increase protection against viral pathogens.
A team from the Broad Institute at MIT and Harvard have designed a Cas13–CRISPR construct, termed CARVER, that can detect and kill viruses inside human cells. The flexible CARVER system could be used as a new tool in research and the clinic.
In this interview we speak to Vincent Racaniello, Professor of Microbiology & Immunology, about his work on polio, picornaviruses and publicizing science through blogs and podcasts.
Take a look behind the scenes of a recent Future Virology review, entitled: ‘TRIM proteins: an emerging antiviral protein family’, as we ask the authors about TRIM proteins, viral resistance and the future of this field.
Take a look behind the scenes of a recent Future Virology review entitled ‘Antiviral therapeutic approaches for human rhinovirus infections’ as we ask author Peter Barlow about antivirals, antibodies and the host response.
Researchers have pioneered novel, gold nanoparticles, which bind and deform viruses rendering them inactive, thereby presenting potential in the development of a broad-spectrum antiviral.
Researchers have identified a new treatment approach for acute HIV-infected patients, which targets human proteins rather than the virus.
For the first time, physicists have created a 3D movie that demonstrates a virus preparing to infect a healthy cell via genomic rearrangement – leading to the potential to better treat an array of human diseases caused by viruses.
This review aims to provide a better understanding of HEV71 virology and potential antivirals for progressive clinical development with respect to their elucidated mechanistic actions.
A new systematic evidence review has discovered that FDA-approved direct-acting antiviral regimens are effective against all genotypes of hepatitis C.